EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Survivorship program including long‐term toxicities and quality‐of‐life development over 10 years in a randomized trial in operable stage III non‐small‐cell lung cancer ( ESPATUE )

Christina Schulte, Thomas Gauler, Christoph Pöttgen, Godehard Friedel, Hans-Georg Kopp, Berthold Fischer, Heinz Schmidberger, Martin Kimmich, Wilfried Budach, Sebastian Cordes, Johannes Wienker, Martin Metzenmacher und 15 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35131 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Christina Schulte und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University Hospital and Ruhrlandklinik, West German Cancer Center, Essen, Germany. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Quality of Life, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Krebshilfe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over 40% stage‐III non‐small‐cell lung cancer (NSCLC) patients (pts) experience 5‐year survival following multimodality treatment. Nevertheless, little is known about relevant late toxicities and quality‐of‐life (QoL) in the further long‐term follow‐up. Therefore, we invited pts from our randomized phase‐III trial (Eberhardt et al., Journal of Clinical Oncology 2015) after 10 years from diagnosis to participate within a structured survivorship program (SSP) including follow‐up imaging, laboratory parameters, cardio‐pulmonary investigations, long‐term toxicity evaluations and QoL questionnaires. Of 246 pts initially accrued, 161 were considered potentially resectable following the induction therapy and were randomized (80 to arm A: definitive chemoradiation; 81 to arm B: definitive surgery; 85 not randomized for different reasons; group C). 31 from 37 pts still alive after 10 years agreed to the SSP (13 in A; 12 in B; 6 in C). Clinically relevant long‐term toxicities (grade 3 and 4) were rarely observed with no signal favoring any of the randomization arms. Furthermore, available data from the global QoL analysis did not show a signal favoring any definitive locoregional approach (Mean QoL in SSP A pts: 56.41/100, B pts: 64.39/100) and no late decline in comparison to baseline and early 1‐year follow‐up. This is the first comprehensive SSP of very late survival follow‐up reported in stage‐III NSCLC treated within a randomized multimodality trial and it may serve as important baseline information for physicians and pts deciding for a locoregional treatment option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungQuality of LifeLung NeoplasmsHumansFemaleMaleAgedMiddle AgedSurvivorshipNeoplasm StagingChemoradiotherapyFollow-Up StudiesAdult

Stichwörter der Autor:innen

NSCLCmultimodality treatmentoperablestage IIIsurvivorship

Autor:innen und Institutionen

  • Department of Medical Oncology, University Hospital and Ruhrlandklinik, West German Cancer Center, Essen, Germany.
  • Department of Radiation Oncology, University Hospital Essen, Essen, Germany.
  • Department of Thoracic Surgery, Universitätsklinikum Tübingen, Universität Tübingen, Tübingen, Germany.
  • Department of Medical Oncology, Robert-Bosch Krankenhaus, Stuttgart, Germany.
  • Department of Pulmonology, University Medicine Mainz, Mainz, Germany.
  • Department of Radiation Oncology, University Medicine Mainz, Mainz, Germany.

ORCID-Profile: Wilfried Ernst Erich Eberhardt

Förderung

  • Deutsche Krebshilfe

Zitieren

APA

Schulte, C., Gauler, T., Pöttgen, C., Friedel, G., Kopp, H. G., Fischer, B., Schmidberger, H., Kimmich, M., Budach, W., Cordes, S., Wienker, J., Metzenmacher, M., de Los Rios, R. H., Spengler, W., De Ruysscher, D., Belka, C., Welter, S., Luetke-Brintrup, D., Guberina, M., …, & Eberhardt, W. E. E. (2025). Survivorship program including long‐term toxicities and quality‐of‐life development over 10 years in a randomized trial in operable stage III non‐small‐cell lung cancer ( ESPATUE ). International Journal of Cancer. https://doi.org/10.1002/ijc.35131

Vancouver

Schulte C, Gauler T, Pöttgen C, Friedel G, Kopp HG, Fischer B, et al. Survivorship program including long‐term toxicities and quality‐of‐life development over 10 years in a randomized trial in operable stage III non‐small‐cell lung cancer ( ESPATUE ). International Journal of Cancer. 2025. doi:10.1002/ijc.35131

BibTeX
@article{Schulte2025,
  author = {Schulte, Christina and Gauler, Thomas and Pöttgen, Christoph and Friedel, Godehard and Kopp, Hans-Georg and Fischer, Berthold and Schmidberger, Heinz and Kimmich, Martin and Budach, Wilfried and Cordes, Sebastian and Wienker, Johannes and Metzenmacher, Martin and de Los Rios, Rodrigo Hepp and Spengler, Werner and De Ruysscher, Dirk and Belka, Claus and Welter, Stefan and Luetke-Brintrup, Diana and Guberina, Maja and Oezkan, Filiz and Darwiche, Kaid and Schuler, Martin and Jöckel, Karl-Heinz and Aigner, Clemens and Stamatis, Georgios and Stuschke, Martin and Eberhardt, Wilfried Ernst Erich},
  title = {Survivorship program including long‐term toxicities and quality‐of‐life development over 10 years in a randomized trial in operable stage III non‐small‐cell lung cancer ( ESPATUE )},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35131}
}
Kostenlos starten →